Lighthouse Pharmaceuticals
Summary active Updated Apr 30, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Lighthouse Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel small-molecule therapies for neurodegenerative and inflammatory diseases 1. The company is based at the Buck Institute for Research on Aging in Novato, California 12. Its lead program, LHP588, is a next-generation gingipain inhibitor being evaluated in the SPRING trial — a Phase 2, double-blind, placebo-controlled study in patients with P. gingivalis-positive mild to moderate Alzheimer’s disease 12. The SPRING trial is supported by a $49.2 million grant from the National Institute on Aging 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-04-28 | Series A | $12M | Double Point Ventures | New and existing investors 1 |
In connection with the financing, Campbell Murray, M.D., a partner at Double Point Ventures, joined Lighthouse’s Board of Directors 1.
What Investors Say
“Lighthouse is pursuing a distinctive and focused approach in Alzheimer’s disease. With LHP588, the company is targeting an important and underexplored biological driver.” — Campbell Murray, Partner, Double Point Ventures 1
What Founders Say
“This financing, together with the support from the NIA, gives Lighthouse the resources to efficiently execute the SPRING trial and advance LHP588 toward late-stage development.” — Casey Lynch, CEO, Lighthouse Pharmaceuticals 1
Sources
-
PR Newswire, “Lighthouse Pharmaceuticals Closes $12 Million Series A Financing Led by Double Point Ventures,” April 28, 2026. https://www.prnewswire.com/news-releases/lighthouse-pharmaceuticals-closes-12-million-series-a-financing-led-by-double-point-ventures-302754665.html↩↩↩↩↩↩↩↩
-
Lighthouse Pharmaceuticals company website, accessed April 2026. https://www.lighthousepharma.com/↩↩